Don't miss the moon pass close to Saturn and Neptune on July 15
Heads up stargazers! The moon will rise close to Saturn and the ice giant Neptune in the eastern sky on the night of July 15, close enough to be seen together in a pair of binoculars!
Saturn will rise above the eastern horizon beneath the stars of the constellation Pisces shortly before midnight for viewers in the U.S. on July 15, with the waning gibbous moon shining roughly three degrees to its upper right. For context, the width of your little finger held at arms length against the night sky accounts for roughly 1 degree.
The planet Neptune can also be found lurking approximately 1 degree to the upper left of Saturn around this time, though its dim brightness, or magnitude of +7.8, will make it impossible to see with the naked eye. Remember: magnitude is the scale used by astronomers to measure the apparent brightness of night sky objects. The lower the number, the brighter a planet or star will appear in the night sky. The human eye is capable of picking out objects with a brightness of +6.5 or greater from a dark sky location.
All three celestial targets will fit nicely within the field of view of a pair of 10x50 binoculars, though Neptune will appear as nothing more than a dim point of blueish light —if it's visible at all against the glare of the waning moon — so don't expect much too much from the ice giant.
Gazing through a telescope with a 6-inch aperture will help reveal the rings around Saturn, while an 8-inch scope may allow you to spot variations in color on the gas giant's cloud surface. A range of exciting observing targets will also be visible on the 75%-lit moon on July 15, including the long, thin form of Mare Frigolis — a vast basalt plain visible as a dark scar running across the northern extreme of the lunar surface.
The celestial trio will remain close to each other throughout the night, with Saturn and Neptune eventually fading from sight in the southern sky when the sun rises on July 16.
Stargazers looking to get a closer look at the myriad worlds of our solar system should check out our guides to the best telescopes and binoculars for exploring the night sky. We also have a handy roundup of the best cameras and lenses for astrophotography for those looking to immortalize their skywatching sessions.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
'Like a sci-fi movie': US baby born from 30-year-old frozen embryo breaks record
A baby boy has been born to an Ohio couple from an embryo that was frozen for more than 30 years, reportedly setting a new world record. Lindsey, 35, and Tim Pierce, 34, welcomed their son, Thaddeus Daniel Pierce, on Saturday. Ms Pierce told MIT Technology Review her family thought "it's like something from a sci-fi movie". It is believed to be longest that an embryo has been frozen before resulting in a successful live birth. The previous record-holder was a pair of twins who were born in 2022 from embryos frozen in 1992. The Pierces had tried to have a child for seven years before they decided to adopt the embryo Linda Archerd, 62, made with her then-husband in 1994 through IVF. At the time, Ms Archerd initially created four embryos. One become her now-30-year-old daughter, and the other three were left in storage. Despite separating from her husband, she did not want to get rid of the embryos, donate them for research or give them to another family anonymously. She said it was important that she was involved with the baby, as they would be related to her adult daughter. Ms Archerd paid thousands of dollars a year for storage until she found a Christian embryo adoption agency, Nightlight Christian Adoptions, which runs a programme known as Snowflakes. Many of these agencies consider their programmes to be saving lives. The programme used by Ms Archerd allows donors to choose a couple, meaning they can state religious, racial and nationality preferences. Ms Archerd's preference was for a married Caucasian, Christian couple living in the US, as she didn't want to "go out of the country", she told MIT Technology Review. She ultimately matched with the Pierces. The IVF clinic in Tennessee at which the couple underwent the procedure, Rejoice Fertility, said its aim was to transfer any embryo it received, no matter the age or conditions. Ms Pierce said she and her husband did not set out to "break any records", but just "wanted to have a baby". Ms Archerd told MIT Technology Review she had not met the baby in person yet, but could already see a resemblance with her daughter. The Americans who 'adopt' other people's embryos
Yahoo
35 minutes ago
- Yahoo
Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025
SOUTH SAN FRANCISCO, Calif., July 31, 2025--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, August 7, 2025, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2026 first quarter ended June 30, 2025, and provide a corporate update. The conference call is being webcast live, and a link can be found under "Events" in the Investors section of the Company's website. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes before the call. The webcast will be archived on Vistagen's website shortly after the call and will be available for at least 90 days. For participants interested in participating in the call via dial-in, please follow the link below to pre-register. After registering, you will be provided with access details via email. About Vistagen Headquartered in South San Francisco, CA, Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to rapidly activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. They are designed to achieve therapeutic benefits without requiring absorption into the blood or uptake into the brain, giving them the potential to be a safer alternative to other pharmacological options if successfully developed and approved. Vistagen is passionate about developing transformative treatment options to improve the lives of individuals underserved by the current standard of care for multiple highly prevalent indications, including social anxiety disorder, major depressive disorder, and multiple women's health conditions, including vasomotor symptoms (hot flashes) associated with menopause. Connect at View source version on Contacts Investor Inquiries: Mark A. McPartlandmarkmcp@ Media Inquiries: Michelle P. Wellingtonmwellington@ Sign in to access your portfolio


Business Wire
39 minutes ago
- Business Wire
Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, August 7, 2025, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2026 first quarter ended June 30, 2025, and provide a corporate update. The conference call is being webcast live, and a link can be found under ' Events ' in the Investors section of the Company's website. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes before the call. The webcast will be archived on Vistagen's website shortly after the call and will be available for at least 90 days. For participants interested in participating in the call via dial-in, please follow the link below to pre-register. After registering, you will be provided with access details via email. About Vistagen Headquartered in South San Francisco, CA, Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to rapidly activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. They are designed to achieve therapeutic benefits without requiring absorption into the blood or uptake into the brain, giving them the potential to be a safer alternative to other pharmacological options if successfully developed and approved. Vistagen is passionate about developing transformative treatment options to improve the lives of individuals underserved by the current standard of care for multiple highly prevalent indications, including social anxiety disorder, major depressive disorder, and multiple women's health conditions, including vasomotor symptoms (hot flashes) associated with menopause. Connect at